<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340506</url>
  </required_header>
  <id_info>
    <org_study_id>CDRB436X2X02B</org_study_id>
    <nct_id>NCT03340506</nct_id>
  </id_info>
  <brief_title>Dabrafenib and/or Trametinib Rollover Study</brief_title>
  <official_title>Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to provide access for patients who are receiving treatment with dabrafenib
      and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs
      or a former GSK-sponsored study who have fulfilled the requirements for the primary
      objective, and who are judged by the investigator as benefiting from continued treatment in
      the parent study as judged by the Investigator at the completion of the parent study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2017</start_date>
  <completion_date type="Anticipated">July 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurences of adverse events to evaluate long term safety and tolerability of dabrafenib, trametinib or combination</measure>
    <time_frame>Baseline up to approximately 5 years</time_frame>
    <description>Clinical and laboratory assessments should be completed based on the local standard of care and physician practice for routine safety monitoring. More frequent examinations may be performed at the Investigator's discretion if medically indicated. Any abnormalities considered clinically significant, induce clinical signs or symptoms, or require changes in treatment constitute an adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Assessment by investigator</measure>
    <time_frame>Baseline up to approximately 5 years</time_frame>
    <description>To evaluate clinical benefit as assessed by the Investigator</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Melanoma</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Solid Tumor</condition>
  <condition>Rare Cancers</condition>
  <condition>High Grade Glioma</condition>
  <arm_group>
    <arm_group_label>dabrafenib monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this study may receive:
- monotherapy of dabrafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trametinib monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this study may receive:
- monotherapy of trametinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy (dabrafenib &amp; trametinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this study may receive:
- the combination of dabrafenib and trametinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabrafenib</intervention_name>
    <description>dabrafenib is available in capsules (50mg and 75mg) taken twice a day</description>
    <arm_group_label>Combination therapy (dabrafenib &amp; trametinib)</arm_group_label>
    <arm_group_label>dabrafenib monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trametinib</intervention_name>
    <description>trametinib is available in tablets (0.5mg, 2mg dose)</description>
    <arm_group_label>Combination therapy (dabrafenib &amp; trametinib)</arm_group_label>
    <arm_group_label>trametinib monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or
             combination within a Novartis or former GSK sponsored study which has fulfilled the
             requirements for the primary objective.

          -  In the opinion of the Investigator would benefit from continued treatment.

        Exclusion Criteria:

          -  Patient has been previously permanently discontinued from study treatment in the
             parent protocol.

          -  Patient's indication is commercially available and reimbursed in the local country.

          -  Patient currently has unresolved toxicities for which dabrafenib and/or trametinib
             dosing has been interrupted in the parent study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Neuckranz</last_name>
      <phone>623-238-7671</phone>
      <email>Angela.Neuckranz@HonorHealth.com</email>
    </contact>
    <investigator>
      <last_name>Michael Gordon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Cancer Hospital and Solove Research Institute Ohio State</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lois Nguapa</last_name>
      <phone>614-366-7421</phone>
      <email>Lois.Nguapa@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Kari L. Kendra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Jimenez</last_name>
      <phone>972-566-3000</phone>
      <email>JJimenez@MaryCrowley.Org</email>
    </contact>
    <investigator>
      <last_name>Minal Barve</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1125ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>H 1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tafinlar</keyword>
  <keyword>Mekinist</keyword>
  <keyword>Dabrafenib</keyword>
  <keyword>Trametinib</keyword>
  <keyword>Adult</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Melanoma Stage IV</keyword>
  <keyword>Metastatic Melanoma</keyword>
  <keyword>Advanced Melanoma</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>NSLC</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>BRAF V600 Mutation</keyword>
  <keyword>BRAF Gene Mutation</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Rare cancers</keyword>
  <keyword>High Grade Glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

